<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424968</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-33058</org_study_id>
    <secondary_id>NCI-2015-00567</secondary_id>
    <secondary_id>351</secondary_id>
    <secondary_id>BMT288</secondary_id>
    <secondary_id>P01CA049605</secondary_id>
    <nct_id>NCT02424968</nct_id>
  </id_info>
  <brief_title>CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma</brief_title>
  <official_title>Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidative Therapy After Non-myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Leukemia and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Lowsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work&#xD;
      as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant&#xD;
      in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and&#xD;
      anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of&#xD;
      cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.&#xD;
      When the healthy stem cells from a donor are infused into the patient they may help the&#xD;
      patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Sometimes the transplanted cells from a donor can make an immune response against the body's&#xD;
      normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate&#xD;
      mofetil after the transplant may stop this from happening. Once the donated stem cells begin&#xD;
      working, the patient's immune system may see the remaining cancer cells as not belonging in&#xD;
      the patient's body and destroy them. Giving an infusion of the donor's white blood cells,&#xD;
      such as CD8+ memory T-cells, may boost this effect and may be an effective treatment to kill&#xD;
      any cancer cells that may be left in the body (consolidative therapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants undergo total lymphoid irradiation (TLI) on Days -11 to -7 and Days -4 to -1 and&#xD;
      receive anti-thymocyte globulin (ATG) per standard institutional practice on Days -11 to -7.&#xD;
      Patients also receive oral cyclosporine daily starting on Day -3, and will continue for at&#xD;
      least 6 months post-transplant. Patients undergo standard non-myeloablative allogeneic HSCT&#xD;
      on Day 0. Patients also receive oral mycophenolate mofetil daily beginning on Day 0 and&#xD;
      continuing until Day 28. Participants receive an intravenous infusion of allogeneic cluster&#xD;
      of differentiation 8 (CD8)+ memory T-cells over 10 to 20 minutes sometime between day 30 and&#xD;
      day 60.&#xD;
&#xD;
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the rate of conversion to full-donor chimerism (FDC) following a&#xD;
      post-transplant infusion (Day 30-60) of freshly-enriched allogeneic CD8+ memory T-cells in&#xD;
      patients with acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), chronic lymphocytic&#xD;
      leukemia (CLL), or Hodgkin lymphoma (HL), who received standard non-myeloablative total&#xD;
      lymphoid irradiation (TLI) anti-thymocyte globulin (ATG) transplant conditioning.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the risk of disease progression, overall and event free survival, and&#xD;
      non-relapse mortality.&#xD;
&#xD;
      II. To determine the incidence of acute and chronic graft-versus-host disease (GVHD)&#xD;
      following the infusion of allogeneic CD8+ memory T-cells.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo TLI on days -11 to -7 and -4 to -1 and receive ATG per standard&#xD;
      institutional practice on days -11 to -7. Patients also receive cyclosporine orally (PO)&#xD;
      daily starting on day -3 and will continue for at least 6 months post-transplant. Patients&#xD;
      undergo non-myeloablative allogeneic hematopoietic stem cell transplant (HSCT) on day 0.&#xD;
      Patients also receive mycophenolate mofetil PO daily beginning on day 0 and continue until&#xD;
      day 28. Based on the patient's status after the initial transplant, patients receive CD8+&#xD;
      memory T-cells intravenously (IV) over 10-20 minutes sometime between day 30 and day 60.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">July 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full-dose Donor Chimerism (FDC)</measure>
    <time_frame>3 months</time_frame>
    <description>A measure of success for the therapeutic infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells is full-dose donor chimerism (FDC). This means to achieve ≥ 95% donor cells in either the CD3+ blood cell lineage or whole blood, within 90 days of the allogeneic CD8+ memory T-cell infusion. The outcome is reported as the number of participants that achieve FDC within 90 days, a number without dispersion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS</measure>
    <time_frame>1 year</time_frame>
    <description>Event-free survival (EFS) is defined as the number of transplant recipients of allogeneic cluster of differentiation 8 (CD8+) memory T-cells that remain alive at 12 months after transplant without disease relapse. Relapse is defined as bone marrow blasts &gt; 5% . The outcome is expressed as the number of allogeneic CD8+ memory T-cell recipients remaining alive at 1 year after transplant without disease relapse, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Graft vs Host Disease (GvHD)</measure>
    <time_frame>Up to 30 days post-infusion</time_frame>
    <description>Occurrence of acute graft vs host disease (aGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience aGvHD within 30 days of the cellular infusion, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOWSKY Grade 3 or Higher Toxicities</measure>
    <time_frame>Up to 60 days post-infusion</time_frame>
    <description>Related adverse events, ie, toxicities, ≥ Grade 3 are significant considerations in the treatment of study participants receiving allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cells transplant recipients who experienced ≥ Grade 3 toxicity within 60 days of infusion of the allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft vs Host Disease (GvHD)</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of chronic graft vs host disease (cGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience cGvHD more 30 days but within 1 year of the cellular infusion, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality (NRM)</measure>
    <time_frame>1 year</time_frame>
    <description>Non-relapse mortality (NRM) is defined as death without known disease relapse or recurrence. The outcome is expressed as the number of allogeneic CD8+ memory T-cells tr. ansplant recipients whose cause of death was not disease relapse or recurrence, a number without dispersion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival (OS) is defined as remaining alive 12 months after the infusion of allogeneic cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cell transplant recipients remaining alive at 12 months after the cellular infusion, a number without dispersion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression (TDP)</measure>
    <time_frame>1 year</time_frame>
    <description>Whether or not the treated disease returns, known as disease progression or relapse, is a measure of treatment efficacy. Recipients of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells were monitored for disease progression through 1 year after the cellular infusion. The outcome is reported as the number of allogeneic CD8+ memory T-cells recipients that experienced disease progression within 12 months (1 year).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given per standard institutional practice</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant</intervention_name>
    <description>Undergo nonmyeloablative allogeneic HSCT</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplant</other_name>
    <other_name>NST</other_name>
    <other_name>Peripheral Blood Stem Cell (PBSC) Transplant</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells</intervention_name>
    <description>Receive CD8+ memory T-cells via IV</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
    <other_name>Allogeneic Lymphocytes</other_name>
    <other_name>Tumor-Derived Lymphocyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Nodal Irradiation</intervention_name>
    <description>Undergo TLI</description>
    <arm_group_label>Infusion of Allogeneic CD8+ Memory T-cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a human leukocyte antigen (HLA)-matched or single allele-mismatched adult&#xD;
             sibling serving as donor&#xD;
&#xD;
          -  Must have a myeloid or lymphoid malignant disease that is treated with TLI and ATG&#xD;
             reduced intensity conditioning for allogeneic transplant (any of the following AML,&#xD;
             myelodysplastic syndrome [MDS], myeloproliferative disease [MPD], CLL, B or T-cell&#xD;
             NHL, HL)&#xD;
&#xD;
          -  Patients who due to age, pre-existing medical conditions, or, prior therapy are&#xD;
             considered to be at high risk for regimen related toxicity associated with fully&#xD;
             ablative transplant conditioning, and therefore reduced intensity conditioning is&#xD;
             recommended&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document;&#xD;
             patients must have signed informed consent to participate in the trial&#xD;
&#xD;
          -  DONOR: Must be an HLA-matched or single allele mismatched sibling of enrolled&#xD;
             transplant patient&#xD;
&#xD;
          -  DONOR: Must be 18-75 years of age, inclusive&#xD;
&#xD;
          -  DONOR: Must be in a state of general good health and have completed a donor evaluation&#xD;
             with history, medical examination and standard blood tests within 35 days of starting&#xD;
             the hematopoietic cell collection procedure; in order to fairly represent the&#xD;
             interests of the donor, the donor evaluation and consent will be performed by a study&#xD;
             team member other than the recipient's attending physician&#xD;
&#xD;
          -  DONOR: Must have a white blood cell count &gt; 3.5 x 10^9/liter, platelets &gt; 150 x&#xD;
             10^9/liter and hematocrit &gt; 35%&#xD;
&#xD;
          -  DONOR: Must be capable of undergoing leukapheresis&#xD;
&#xD;
          -  DONOR: Must be able to understand and sign informed consent&#xD;
&#xD;
          -  DONOR: Must not be seropositive for HIV 1 and 2, hepatitis B surface antigen,&#xD;
             hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus&#xD;
             (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema); donors with&#xD;
             prior evidence of hepatitis B core antibody positivity will have a polymerase chain&#xD;
             reaction (PCR) test done to evaluate for hepatitis B infection; donors with a positive&#xD;
             hepatitis B PCR test are excluded&#xD;
&#xD;
          -  DONOR: Females must not be pregnant or lactating&#xD;
&#xD;
          -  DONOR: Must not have psychological traits or psychological or medical conditions which&#xD;
             make them unlikely to tolerate the procedure&#xD;
&#xD;
          -  DONOR: Must not have developed a new malignancy requiring chemotherapy or radiation in&#xD;
             the interval since apheresis for initial hematocrit (HCT)&#xD;
&#xD;
          -  PATIENT CRITERIA FOR PROCEEDING WITH CD8+ MEMORY T-CELL INFUSION:&#xD;
&#xD;
          -  Patients must be beyond day 30 and before day 60 after transplant&#xD;
&#xD;
          -  Patients must have evidence of mixed CD3 T-cell chimerism based on the day +28 (+/- 7&#xD;
             days) blood sample showing &gt;= 5% and =&lt; 95% donor type cells&#xD;
&#xD;
          -  Patients must have no evidence of active graft-versus-host disease at the time of the&#xD;
             CD8+ memory T-cell infusion; patients with a history of acute GVHD overall grade II&#xD;
             based on skin only involvement or upper gastrointestinal (GI) tract involvement only&#xD;
             will be eligible; patients with a history of liver or lower GI tract GVHD will not be&#xD;
             eligible&#xD;
&#xD;
          -  Patients must be on single immune suppression therapy with either tacrolimus or&#xD;
             cyclosporine at the time of CD8+ memory T-cell infusion; prednisone at a physiologic&#xD;
             dose of 5 mg per day or less is allowed&#xD;
&#xD;
          -  Patients must have a Karnofsky performance status of &gt;= 60% at the time of the CD8+&#xD;
             memory T-cell infusion&#xD;
&#xD;
          -  Patients must not have an uncontrolled bacterial, fungal or viral infection, defined&#xD;
             as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell&#xD;
             infusion; asymptomatic viremia is allowed&#xD;
&#xD;
          -  Patients must have adequate organ function and performance status at the time of the&#xD;
             CD8+ memory T-cell infusion, defined by the following:&#xD;
&#xD;
               -  Total bilirubin =&lt; 4 mg/dL&#xD;
&#xD;
               -  SGOT or SGPT =&lt; 4 x ULN&#xD;
&#xD;
               -  Creatinine =&lt; 3 mg/dL or estimated creatinine clearance &gt;= 40ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infection defined as currently taking&#xD;
             medication and progression of clinical symptoms&#xD;
&#xD;
          -  Progressive hemato-lymphoid malignancy despite conventional therapy&#xD;
&#xD;
          -  Acute leukemia not in remission&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML)&#xD;
&#xD;
          -  Active central nervous system (CNS) involvement of the underlying malignancy&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Prior malignancy (EXCEPTION: diagnosed &gt; 5 years ago without evidence of disease, OR&#xD;
             treated =&lt; 5 years ago but have a greater than 50% chance of life expectancy of &gt;= 5&#xD;
             years for that malignancy)&#xD;
&#xD;
          -  Have a psychiatric disorder(s) or psychosocial circumstance(s) which in the opinion of&#xD;
             the primary physician would place the patient at an unacceptable risk from transplant&#xD;
&#xD;
          -  Ejection fraction &lt; 30%, or uncontrolled cardiac failure&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 40% predicted&#xD;
&#xD;
          -  Total bilirubin &gt; 3 mg/dL&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) &gt; 4 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &gt; 2 mg/dL and an estimated creatinine clearance =&lt; 40 mL/min&#xD;
&#xD;
          -  Poorly controlled hypertension despite multiple antihypertensive medication OR&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &lt; 60%&#xD;
&#xD;
          -  Note: Patients positive for hepatitis B and C will be evaluated on a case by case&#xD;
             basis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 16, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <results_first_submitted>June 1, 2021</results_first_submitted>
  <results_first_submitted_qc>June 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2021</results_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Lowsky</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Healthy Stem Cell Donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02424968/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02424968/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
          <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
          <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Full-dose Donor Chimerism (FDC)</title>
        <description>A measure of success for the therapeutic infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells is full-dose donor chimerism (FDC). This means to achieve ≥ 95% donor cells in either the CD3+ blood cell lineage or whole blood, within 90 days of the allogeneic CD8+ memory T-cell infusion. The outcome is reported as the number of participants that achieve FDC within 90 days, a number without dispersion.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Full-dose Donor Chimerism (FDC)</title>
          <description>A measure of success for the therapeutic infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells is full-dose donor chimerism (FDC). This means to achieve ≥ 95% donor cells in either the CD3+ blood cell lineage or whole blood, within 90 days of the allogeneic CD8+ memory T-cell infusion. The outcome is reported as the number of participants that achieve FDC within 90 days, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS</title>
        <description>Event-free survival (EFS) is defined as the number of transplant recipients of allogeneic cluster of differentiation 8 (CD8+) memory T-cells that remain alive at 12 months after transplant without disease relapse. Relapse is defined as bone marrow blasts &gt; 5% . The outcome is expressed as the number of allogeneic CD8+ memory T-cell recipients remaining alive at 1 year after transplant without disease relapse, a number without dispersion.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS</title>
          <description>Event-free survival (EFS) is defined as the number of transplant recipients of allogeneic cluster of differentiation 8 (CD8+) memory T-cells that remain alive at 12 months after transplant without disease relapse. Relapse is defined as bone marrow blasts &gt; 5% . The outcome is expressed as the number of allogeneic CD8+ memory T-cell recipients remaining alive at 1 year after transplant without disease relapse, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Acute Graft vs Host Disease (GvHD)</title>
        <description>Occurrence of acute graft vs host disease (aGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience aGvHD within 30 days of the cellular infusion, a number without dispersion.</description>
        <time_frame>Up to 30 days post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Graft vs Host Disease (GvHD)</title>
          <description>Occurrence of acute graft vs host disease (aGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience aGvHD within 30 days of the cellular infusion, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LOWSKY Grade 3 or Higher Toxicities</title>
        <description>Related adverse events, ie, toxicities, ≥ Grade 3 are significant considerations in the treatment of study participants receiving allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cells transplant recipients who experienced ≥ Grade 3 toxicity within 60 days of infusion of the allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells, a number without dispersion.</description>
        <time_frame>Up to 60 days post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>LOWSKY Grade 3 or Higher Toxicities</title>
          <description>Related adverse events, ie, toxicities, ≥ Grade 3 are significant considerations in the treatment of study participants receiving allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cells transplant recipients who experienced ≥ Grade 3 toxicity within 60 days of infusion of the allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft vs Host Disease (GvHD)</title>
        <description>The incidence of chronic graft vs host disease (cGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience cGvHD more 30 days but within 1 year of the cellular infusion, a number without dispersion.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft vs Host Disease (GvHD)</title>
          <description>The incidence of chronic graft vs host disease (cGvHD) following the infusion of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells will be assessed. The outcome is reported as the number of allogeneic CD8+ memory T-cell recipients who experience cGvHD more 30 days but within 1 year of the cellular infusion, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality (NRM)</title>
        <description>Non-relapse mortality (NRM) is defined as death without known disease relapse or recurrence. The outcome is expressed as the number of allogeneic CD8+ memory T-cells tr. ansplant recipients whose cause of death was not disease relapse or recurrence, a number without dispersion</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality (NRM)</title>
          <description>Non-relapse mortality (NRM) is defined as death without known disease relapse or recurrence. The outcome is expressed as the number of allogeneic CD8+ memory T-cells tr. ansplant recipients whose cause of death was not disease relapse or recurrence, a number without dispersion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) is defined as remaining alive 12 months after the infusion of allogeneic cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cell transplant recipients remaining alive at 12 months after the cellular infusion, a number without dispersion</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) is defined as remaining alive 12 months after the infusion of allogeneic cluster of differentiation 8 (CD8+) memory T-cells. The outcome is reported as the number of allogeneic CD8+ memory T-cell transplant recipients remaining alive at 12 months after the cellular infusion, a number without dispersion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression (TDP)</title>
        <description>Whether or not the treated disease returns, known as disease progression or relapse, is a measure of treatment efficacy. Recipients of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells were monitored for disease progression through 1 year after the cellular infusion. The outcome is reported as the number of allogeneic CD8+ memory T-cells recipients that experienced disease progression within 12 months (1 year).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
            <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression (TDP)</title>
          <description>Whether or not the treated disease returns, known as disease progression or relapse, is a measure of treatment efficacy. Recipients of allogeneic transplantation of cluster of differentiation 8 (CD8+) memory T-cells were monitored for disease progression through 1 year after the cellular infusion. The outcome is reported as the number of allogeneic CD8+ memory T-cells recipients that experienced disease progression within 12 months (1 year).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>Per protocol, Grade 1 to 2 adverse events were not collected. Grade 3 and higher adverse events were collected through 90 days (3 months) after the CD8+ memory T-cell infusion. Per protocol, policy, and practice, mortality (survival) is collected indefinitely.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infusion of Allogeneic CD8+ Memory T-cells</title>
          <description>All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).&#xD;
Anti-Thymocyte Globulin: Given per standard institutional practice&#xD;
Cyclosporine: Given PO&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant: Undergo nonmyeloablative allogeneic HSCT&#xD;
Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells: Receive CD8+ memory T-cells via IV&#xD;
Total Nodal Irradiation: Undergo TLI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Lowsky, Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-0822</phone>
      <email>rlowsky@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

